开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R54
R692

References50

[1]	Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic?[J]. Curr Opin Rheumatol, 2020, 32(1): 71-79. doi:10.1097/BOR.0000000000000679 URL
[2]	Waheed Y, Yang F, Sun D. The role of asymptomatic hyperuricemia in the progression of chronic kidney disease CKD and cardiovascular diseases CVD[EB/J]. Korean J Intern Med, 2020. https://www.researchgate.net/publication/346312158_The_role_of_asymptomatic_hyperuricemia_ in_the_progression_of_chronic_kidney_disease_CKD_and_cardiovascular_diseases_CVD.
[3]	Pijak MR. A role for asymptomatic hyper-uricemia in the progression of cardiovascular and renal disease[J]. BMJ, 2020, 110(5 Pt 1): 2390-2397.
[4]	Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review[J]. BMC Musculoskelet Disord, 2015, 16:296. doi:10.1186/s12891-015-0762-4 URL
[5]	Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, et al. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats[J]. J Biol Chem, 2019, 294(11): 4272-4281. doi:10.1074/jbc.RA118.006158pmid:30651350
[6]	Li H, Qian F, Liu H, et al. Elevated uric acid levels promote vascular smooth muscle cells (VSMC) proliferation via an nod-Like receptor protein 3 (NLRP3)-inflammasome-dependent mechanism[J]. Med Sci Monit, 2019, 25: 8457-8464. doi:10.12659/MSM.916667 URL
[7]	Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome[J]. Sci Rep, 2017, 739884.
[8]	Yang X, Gu J, Lv H, et al. Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor[J]. Biomed Pharmacother, 2019, 109: 1163-1170. doi:10.1016/j.biopha.2018.10.129 URL
[9]	Liang WY, Zhu XY, Zhang JW, et al. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling[J]. Nutr Metab Cardiovasc Dis, 2015, 25(2): 187-194. doi:10.1016/j.numecd.2014.08.006pmid:25315669
[10]	Sánchez-Lozada LG. The pathophysiology of uric acid on renal diseases[J]. Contrib Nephrol, 2018, 192: 17-24. doi:10.1159/000484274pmid:29393088
[11]	Song M, Li N, Yao Y, et al. Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis[J]. J Cell Mol Med, 2019, 23(8): 4970-4979. doi:10.1111/jcmm.14337 URL
[12]	Gancheva R, Kundurdjiev A, Ivanova M, et al. Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography[J]. Rheumatol Int, 2017, 37(1): 121-130. doi:10.1007/s00296-016-3556-6pmid:27577941
[13]	Kim SC, Di Carli MF, Garg RK, et al. Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome[J]. BMC Rheumatol, 2018, 2: 17. doi:10.1186/s41927-018-0027-6 URL
[14]	Choi HY, Kim SH, Choi AR, et al. Hyperuricemia and risk of increased arterial stiffness in healthy women based on health screening in Korean population[J]. PLoS One, 2017, 12(6): e180406.
[15]	Yan NW, Numthavaj P, Thakkinstian A. Association between uric acid and arterial stiffness in general adults: a systematic review and meta-analysis[J]. Ramathibodi Med J, 2018. https://www.researchgate.net/publication/333080340_Association_Between_Uric_Acid_and_Arterial_Stiffness_in_General_Adults_A_Systematic_Review_ and_Meta-analysis.
[16]	Moriyama K. Low-density lipoprotein subclasses are associated with serum uric acid levels[J]. Clin Lab, 2018, 64(7): 1137-1144. doi:10.7754/Clin.Lab.2018.180108pmid:30146836
[17]	Tayefi M, Hassanian SM, Maftouh M, et al. Relationship between platelet count and platelet width distribution and serum uric acid concentrations in patients with untreated essential hypertension[J]. Biofactors, 2018, 44(6): 532-538. doi:10.1002/biof.1453 URL
[18]	Park JS, Kang S, Ahn CW, et al. Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women[J]. Maturitas, 2012, 73(4): 344-348. doi:10.1016/j.maturitas.2012.09.009 URL
[19]	Feldman RD. Sex-specific determinants of coronary artery disease and atherosclerotic risk factors: estrogen and beyond[J]. Can J Cardiol, 2020, 36(5): 706-711. doi:S0828-282X(20)30219-1pmid:32389343
[20]	Tanaka A, Taguchi I, Teragawa H, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial[J]. PLoS Med, 2020, 17(4): e1003095. doi:10.1371/journal.pmed.1003095 URL
[21]	McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology[J]. Eur Heart J, 2012, 33(14): 1787-1847. doi:10.1093/eurheartj/ehs104pmid:22611136
[22]	Wu X, Jian G, Tang Y, et al. Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities[J]. Nutr Metab Cardiovasc Dis, 2020, 30(4): 666-673. doi:10.1016/j.numecd.2019.12.008 URL
[23]	Pan JA, Lin H, Wang CQ, et al. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia[J]. Heart Vessels, 2020: 35(10):1446-1453. doi:10.1007/s00380-020-01619-8 URL
[24]	Jörgensen G. Serum uric acid concentrations can predict hypertension: a longitudinal population-based epidemiological study[J]. Horm Metab Res, 2017, 49(11): 873-879. doi:10.1055/s-0043-119129 URL
[25]	Zhang J, Diao B, Lin X, et al. TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid[EB/J]. Biochimie, 2019. https://linkinghub.elsevier.com/retrieve/pii/S0300-9084(19)30127-0.
[26]	Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk[J]. Am J Cardiol, 2004, 94(7): 932-935. doi:10.1016/j.amjcard.2004.06.032 URL
[27]	Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity[J]. Hypertension, 2017, 69(2): 339-348. doi:10.1161/HYPERTENSIONAHA.116.08240 URL
[28]	Mazza A, Lenti S, Schiavon L, et al. Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population[J]. Biomed Pharmacother, 2017, 86: 590-594. doi:10.1016/j.biopha.2016.11.104 URL
[29]	Cicero AF, Salvi P, D’Addato S, et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study[J]. J Hypertens, 2014, 32(1): 57-64. doi:10.1097/HJH.0b013e328365b916 URL
[30]	Storhaug HM, Norvik JV, Toft I, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population[J]. BMC Cardiovasc Disord, 2013, 13:115. doi:10.1186/1471-2261-13-115 URL
[31]	Tu W, Wu J, Jian G, et al. Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities[J]. Eur J Clin Nutr, 2019, 73(10): 1392-1402. doi:10.1038/s41430-019-0405-1pmid:30787471
[32]	Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis[J]. Sci Rep, 2016, 6: 19520. doi:10.1038/srep19520 URL
[33]	Gómez M, Vila J, Elosua R, et al. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population[J]. Atherosclerosis, 2014, 232(1): 134-140. doi:10.1016/j.atherosclerosis.2013.10.026 URL
[34]	Suarna C, Dean RT, May J, et al. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1616-1624. doi:10.1161/01.ATV.15.10.1616 URL
[35]	Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis[J]. Cardiovasc Ther, 2012, 30(4): 217-226. doi:10.1111/j.1755-5922.2011.00277.xpmid:22099531
[36]	Kuwano K, Ikeda H, Oda T, et al. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis[J]. Am J Physiol, 1996, 270(6 Pt 2): H1993-H1999.
[37]	Wu J, Lei G, Wang X, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities[J]. Oncotarget, 2017, 8(46): 80688-80699. doi:10.18632/oncotarget.21079 URL
[38]	Rodríguez-Martín S, de Abajo FJ, Gil M, et al. Risk of acute myocardial infarction among new users of allopurinol according to serum urate level[J]. J Clin Med, 2019, 8(12): 2150. doi:10.3390/jcm8122150 URL
[39]	Miranda-Aquino T, Pérez-Topete SE, González-Padilla C, et al. Asymptomatic hyperuricaemia and coronary artery disease[J]. Reumatol Clin (Engl Ed), 2020, 17(5): 263-267.
[40]	Gaubert M, Marlinge M, Alessandrini M, et al. Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome[J]. Purinergic Signal, 2018, 14(2):191-199. doi:10.1007/s11302-018-9604-9 URL
[41]	Jung SW, Kim SM, Kim YG, et al. Uric acid and inflammation in kidney disease[J]. Am J Physiol Renal Physiol, 2020, 318(6): F1327-F1340. doi:10.1152/ajprenal.00272.2019 URL
[42]	Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict?[J]. J Nephrol, 2020, 33(4): 715-724. doi:10.1007/s40620-020-00702-7 URL
[43]	Hu C, Wu X. Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue[J]. Int Urol Nephrol, 2019, 51(12): 2227-2233. doi:10.1007/s11255-019-02256-5 URL
[44]	Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis[J]. Int Urol Nephrol, 2019, 51(6): 1013-1018. doi:10.1007/s11255-019-02154-wpmid:31020628
[45]	Liu X, Wang H, Ma R, et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5[J]. Clin Exp Nephrol, 2019, 23(3): 362-370. doi:10.1007/s10157-018-1652-5 URL
[46]	Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease[J]. N Engl J Med, 2020, 382(26): 2504-2513. doi:10.1056/NEJMoa1915833 URL
[47]	Eleftheriadis T, Golphinopoulos S, Pissas G, et al. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial[J]. J Adv Res, 2017, 8(5): 555-560. doi:10.1016/j.jare.2017.05.001pmid:28748122
[48]	Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia[J]. Am J Kidney Dis, 2018, 72(6): 798-810. doi:10.1053/j.ajkd.2018.06.028 URL
[49]	FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout[J]. Arthritis Care Res(Hoboken), 2020, 72(6): 744-760.
[50]	Hisatome I, Li P, Miake J, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease: Japanese guideline on the management of asymptomatic hyperuricemia[J]. Circ J, 2021, 85(2): 130-138. doi:10.1253/circj.CJ-20-0406pmid:33342914

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References50

Related Articles15

Recommended Articles

Metrics

Comments

[1]	WU Liqun.Greatness in simplicity—new technology of pulmonary vein isolation[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 357-359.
[2]	LI Ruogu.Clinical application of His bundle pacing[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 360-364.
[3]	TANG Baopeng, ZHANG Jianghua, GUO Yankai.Progress in clinical application of leadless pacemaker[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 365-368.
[4]	LIU Ruifeng, SHENG Qianqian, ZHANG Yue, ZHAO Huiqiang.Lymphocyte and monocyte subtypes in coronary artery ectasia patients[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 373-378.
[5]	YIN Xiang, ZHENG Liangrong.Research progress of percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 392-395.
[6]	FEI Zhentao, CHEN Mu, LI Yigang.Research progress on mechanism of atrial fibrillation recurrence after catheter ablation[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 396-399.
[7]	ZHANG Zhi, TANG Xuechao, HUANG Xinmiao, et al.Application of pulsed electric field ablation in atrial fibrillation[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 400-404.
[8]	YANG Ling, ZHA Qing, ZHANG Qianru, YE Jiawen, YANG Ke, LIU Yan.Biomarker-based predictive model for calcific aortic valve disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 324-329.
[9]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 337-338.
[10]	LI Xinni, MA Wenkun, GAO Chengjie, GAO Yajie, JIN Xuejuan, ZHOU Yi, SHEN Chengxing, PAN Jingwei.Influence of different diagnostic criteria on the prevalence of hypertension in the population[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 273-277.
[11]	GAO Jian, WANG Deqin, ZHOU Yonghua, MIAO Xianjing, CHEN Yu, JING Xin, WANG Yan.Study on relationship between serum growth stimulation expressed gene 2 and lipoprotein-associated phospholipase 2 and cardiovascular events in maintenance hemodialysis patients[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 295-300.
[12]	XI Rui, FAN Qin, WANG Fang, TAO Rong, GU Gang.Value of D-dimer combined with cystatin C in predicting the occurrence of major adverse cardiovascular events in patients with acute myocardial infarction undergoing percutaneous coronary intervention[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 227-232.
[13]	HU Jian, YANG Zhenkun, YAN Xiaoxiang, DU Run, DING Fenghua, LIU Jun.Comparison of the efficacy of percutaneous coronary intervention and coronary artery bypass grafting in octogenarian with chronic total occlusion of left anterior descending artery[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(01): 70-72.
[14]	WANG Shun, ZHU Huafang, MAO Chengyu, LI Dongjiu, WANG Changqian.Experimental study of the effect of compound combination of traditional Chinese medicine on atherosclerosis[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 261-266.
[15]	HU Jian, YANG Zhenkun, YAN Xiaoxiang, NI Jun, DING Fenghua.Clinical effect of subintimal stent implantation in the patients with chronic total occlusion in coronary artery[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 230-233.